Product Specific Guidances Webinar – Opening Remarks

Автор: U.S. Food and Drug Administration

Загружено: 2021-06-03

Просмотров: 2298

Описание: Lei Zhang, Deputy Director of the Office of Research and Standards in FDA’s Office of Generic Drugs, explains product specific guidances, provides a background on them, and discusses how they aid in generic drug development.

Learn more at https://www.fda.gov/drugs/fda-product...

_______________________________
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.

Register for upcoming training: https://www.fda.gov/cdersbia
Subscribe to the listserv: https://public.govdelivery.com/accoun...
Watch the 2021 Playlist:    • 2021 CDER Small Business and Industry Assi...

Follow on LinkedIn:   / cder-small-business-and-industry-assistance
Visit training resources: https://www.fda.gov/cdersbialearn
Follow on Twitter:   / fda_drug_info

Email: [email protected]
Phone: (301) 796-6707 I (866) 405-5367

Не удается загрузить Youtube-плеер. Проверьте блокировку Youtube в вашей сети.
Повторяем попытку...

Product Specific Guidances Webinar – Opening Remarks

Доступные форматы для скачивания:

Скачать видео

Информация по загрузке:

Скачать аудио

Похожие видео

FDA Grand Rounds - Advancing Real World Evidence in FDA Regulatory Decision Making

FDA Grand Rounds - Advancing Real World Evidence in FDA Regulatory Decision Making

OTC Monograph Reform: OTC Sunscreen Drugs

OTC Monograph Reform: OTC Sunscreen Drugs

FDA Grand Rounds - Antibody Glycosylation Insights for High Quality Biotherapeutics

FDA Grand Rounds - Antibody Glycosylation Insights for High Quality Biotherapeutics

FDA-USP-AAM | D1S3 - Industry’s Engagement in USP’s Standards-Setting Process

FDA-USP-AAM | D1S3 - Industry’s Engagement in USP’s Standards-Setting Process

Non-Complex Drug Products and Product-Specific Guidances

Non-Complex Drug Products and Product-Specific Guidances

Conversations on Cancer – Perspectives on Cancer Care Decision-Making Among Older Adults

Conversations on Cancer – Perspectives on Cancer Care Decision-Making Among Older Adults

FDA Direct: Combating Rare Diseases at the FDA

FDA Direct: Combating Rare Diseases at the FDA

FDA Grand Rounds - Postmarket Regulation of Cosmetic Products: The Who, What, When, Why, and How

FDA Grand Rounds - Postmarket Regulation of Cosmetic Products: The Who, What, When, Why, and How

Drug Master File (DMF) Submissions on New FDA Form 3938

Drug Master File (DMF) Submissions on New FDA Form 3938

FDA Grand Rounds - Adopting Large Language Models for Regulatory Review

FDA Grand Rounds - Adopting Large Language Models for Regulatory Review

FDA’s Rare Disease Day 2026 – An Event for Patients

FDA’s Rare Disease Day 2026 – An Event for Patients

FDA Grand Rounds - Anti biofilm Technologies for Enhancing the Safety of Medical Device Surfaces

FDA Grand Rounds - Anti biofilm Technologies for Enhancing the Safety of Medical Device Surfaces

FDA-USP-AAM | D1S1 – FDA's Participation in USP-NF Revision Process – Challenges and Solutions

FDA-USP-AAM | D1S1 – FDA's Participation in USP-NF Revision Process – Challenges and Solutions

FDA Expert Panel on Food Allergies

FDA Expert Panel on Food Allergies

FDA Grand Rounds - Forensic Proteomics Applied to FDA Regulated Products

FDA Grand Rounds - Forensic Proteomics Applied to FDA Regulated Products

FDA Grand Rounds - Statistical Considerations for Drug Development in Rare Disease

FDA Grand Rounds - Statistical Considerations for Drug Development in Rare Disease

Bioequivalence Regulations and Product-Specific Guidances

Bioequivalence Regulations and Product-Specific Guidances

FDA's Public Meeting on Food Allergen Thresholds - 02/18/2026

FDA's Public Meeting on Food Allergen Thresholds - 02/18/2026

FDA Celebrates 120 Years

FDA Celebrates 120 Years

FDA-USP-AAM | D1S2 – Strengthening Your Compendial Strategy

FDA-USP-AAM | D1S2 – Strengthening Your Compendial Strategy